secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001437749-24-031805
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene presents RESTORE-ALS Phase 3 trial design for CNM-Au8 at NEALS meeting
----------------------------------------------------------------------------

- Presented preliminary design for RESTORE-ALS, an international Phase 3 trial of CNM-Au8 30 mg for ALS.
- Presentation made at the 2024 Annual NEALS Meeting on October 23, 2024.
- No efficacy or safety results disclosed; only the trial design was shared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924031805/0001437749-24-031805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774924031805/clnn20241022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer